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Background:Oxidative stress occurs inmany neurodegenerative diseases including Alzheimer's disease (AD) and
evidence suggests that speciﬁc proteins are oxidised in individual diseases. Thus measures of oxidised proteins
such as in human biological samples could represent potential disease-speciﬁc biomarkers. Protein carbonylation
is considered to be an important marker of oxidative stress. In AD in particular, the peptidyl prolyl isomerase,
Pin1, has been shown to be sensitive to metal-catalysed oxidation with the addition of carbonyl side-chains.
Methods: Based on this protein modiﬁcation we developed a novel, enzyme-linked sandwich immunoassay for
the quantiﬁcation of oxidised Pin1 (oxPin1) in human brain tissue samples.
Results: We successfully developed an ELISA for the measurement of oxidised Pin1 in biological samples and
measured oxPin1 in hippocampal tissue extracts from controls and AD, which showed an increased ratio of
oxPin1 to total Pin1 in patients with early AD pathology compared with controls.
Conclusions:We show that oxidised proteins, in this case oxPin1, can bemeasured using the developed ELISA. In
addition, our results support the presence of increased oxidative stress in the early stages of AD pathology and
show that the oxPin1/Pin1 ratio could indicate early stage pathology. This warrants further investigation in
other biological ﬂuids.
General signiﬁcance: Importantly, further development and adaption of the assay design will enable
multi-functional use for the quantiﬁcation of oxidised proteins in tissues and biological ﬂuids that may be used
in investigating the role of oxidised proteins in a range of neurodegenerative diseases, particularly in which
disease-speciﬁc protein oxidation has been implicated.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The brain uses more oxygen than any other organ of the body,
making it prone to damage by reactive oxygen species (ROS) produced
by its aerobic activity. ROS are produced continuously and play an
important role in biological processes such as signal transduction,
immune responses and ageing [1]. An imbalance between endogenous
pro-oxidants and antioxidant defences leads to unregulated production
of ROS and subsequent oxidative stress [2] and is implicated in the
progression of neurodegenerative diseases including Alzheimer's
disease (AD) [3].
One of the most important measures currently used to measure
oxidative stress is the quantiﬁcation of the oxidative state of glutathione
(GSH), the most prevalent antioxidant in the brain. In particular, the
ratio between GSH and oxidised glutathione (GSH/GSSG) has been
shown to be decreased in affected regions of AD brain compared with
controls [4]. However, the use of GSH as a measure of oxidative stress
has recently been questioned [5]. Furthermore, GSH/GSSG is a broad
measure of oxidative stress, which is a feature of a wide range of
diseases, and is not a marker for a speciﬁc disease.
Several alternative methods of measuring speciﬁc types of oxidative
stress such as metal-catalysed oxidation, nitration, and methionine
oxidation are also available but, again, these are generally not speciﬁc
for an individual disease [6]. Since there is now increasing evidence
that speciﬁc proteins are oxidised in speciﬁc neurodegenerative
diseases [7–9], the measurement of speciﬁcally oxidised proteins may
represent an alternative with promise for the development of disease-
speciﬁc (oxidised protein) biomarkers. The role of oxidative stress in
AD has been rather extensively studied and several proteins that appear
to be speciﬁcally oxidised have been identiﬁed [7,8]. However, the
measurements currently used, such as 2D gel analysis, chromatography
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and mass spectrometry, are often specialised and time-consuming.
Therefore, a simple effective measure of individually oxidised proteins
would be of signiﬁcant value. Therefore, we aimed to develop a simple
effective method for measuring oxidised proteins and investigated
its use in the detection of speciﬁcally oxidised proteins in AD as an
example.
The oxidation of many proteins results in the addition of carbonyl
groups (aldehydes and ketones) to protein side chains (predominantly
Pro, Arg, Lys, and Thr) [10,11]. In AD, the proteins that appear most
vulnerable to oxidative stress include the peptidyl-prolyl isomerase,
Pin1 and glutamine synthetase (GS) which, when oxidised contain
carbonyl side chains that can be measured [11,12]. Pin1 is of particular
importance to AD, as it binds to phosphorylated tau (p-tau), amyloid
precursor protein (APP) and glycogen synthase kinase-3β (GSK3β), all
of which play a signiﬁcant role in the pathogenesis of AD. Pin1 binds
speciﬁcally to proteins with phosphorylated serine (Ser) or threonine
(Thr) residues preceding a proline residue. Upon binding, Pin1 catalyses
the isomerisation of the protein at the proline residue, twisting it from
cis to trans conformation [13]. Upon Pin1 binding at Thr231, tau is
isomerised to trans conformation, facilitating its dephosphorylation by
the trans-speciﬁc protein phosphatase 2A (PP2A) [14]. Similarly,
processing of APP via the non-amyloidogenic pathway is favoured
when APP is in trans-conformation and binding of Pin1 to APP at
Thr668 reduces production of Aβ42 [15]. Pin1 is also responsible for
inhibition of glycogen-synthase kinase 3β (GSK-3β), which is involved
in the phosphorylation of both APP and tau [16,17]. By binding to
GSK-3β, Pin1 reduces phosphorylation of both APP and tau thus further
reducing amyloidogenic processing of APP and hyperphosphorylation
of tau.When Pin1 is oxidised, its activity is restrained and can no longer
bind to its substrates. The absence of Pin1 may thus correlate with
enhanced amyloidogenic APP processing and increased Aβ42 production
together with hyper-phosphorylation of tau and subsequent formation
of neuroﬁbrillary tangles (NFTs) [7,12].
In this study, we aimed to develop simple, effective means for
measuring levels of speciﬁcally oxidised proteins in human biological
material. As an example, we developed an ELISA for the measurement
of oxidised Pin1 (oxPin1) and used it to measure levels of oxPin1 in
brain tissue at different stages of Alzheimer's disease pathology
compared with cognitively normal controls.
2. Materials and methods
2.1. Tissue samples
Frozen human hippocampal tissues from control and AD patients
were obtained from the Department of Pathology (Radboud UMC) and
were collected using standard protocols. Left over material from autop-
sies was used according to institutional guidelines which were in line
with the Dutch national law. Additional hippocampal samples were
obtained from The Netherlands Brain Bank (NBB, Netherlands Institute
for Neuroscience Amsterdam), collected from donors for or fromwhom
a written informed consent for a brain autopsy and the use of the
material and clinical information for research purposes had been
obtained by the NBB. Tissue samples were taken as quickly as possible
after autopsy and rapidly frozen in liquid nitrogen. Post-mortem diag-
nosis and grading were performed and judged by a neuropathologist,
according to the criteria established by Braak & Braak (all samples)
and CERAD (for RadboudUMC patients only) [18–20]. Clinical diagnosis
of AD was based on the clinical criteria of probable AD [21,22]. Patient
characteristics for all patients are described in Table 1.
Protein extraction from brain tissue was performed by suspending
serial cryosections of hippocampus or cortex (10 μm thickness) in cold
5 M guanidine hydrochloride (GuHCl)/50 mM Tris–HCL, pH 8.0 contain-
ing a protease inhibitor cocktail (Complete Mini, EDTA free, Merck
Millipore, Darmstadt, Germany) and vortexing until the tissue was fully
lysed. Samples were centrifuged for 20 min (16,000 ×g at 4 °C) and the
supernatant was stored at−80 °C in clean polypropylene tubes. Total
protein concentrations were determined using a bicinchoninic acid
(BCA) protein assay kit (Thermo Fisher Scientiﬁc, Rockford, IL, USA).
2.2. Production and puriﬁcation of recombinant Pin1 protein
Recombinant Pin1 protein was produced using a construct of Pin1
cDNA cloned in the pET-46 Ek expression vector (Novagen, Madison,
WI) and OneShot® BL21 (DE3) Star™ cells (Life Technologies, Carlsbad,
CA, USA) by isopropyl β-D-thiogalactoside (ITPG) induction. His-tagged
recombinant protein was puriﬁed under native conditions using a Nick-
el Nitrilotriacetic acid (Ni-NTA) chromatography column (Qiagen,
Hilden, Germany) and elution with imidazole. The protein was cleared
of imidazole using dialysis with phosphate buffered saline and subse-
quently concentrated using a 9 kDa cut-off protein concentrator accord-
ing to the manufacturer's instructions (Thermo Fisher Scientiﬁc,
Rockford, IL, USA). The ﬁnal protein concentration was determined
using the BCA protein assay kit.
2.3. Oxidation of recombinant Pin1 protein
Puriﬁed Pin1 protein (80.8 μL; 0.5 μg/mL; estimated purity ~95%
based on SDS-PAGE gel analysis) was incubated with an oxidation
solution containing 0.2 mM Fe(II)SO4, 10 mM H2O2 and 0.3 mM EDTA
in PBS (pH 7.4) in a ﬁnal volume of 100 μL for 3 h [12]. One microliter
of 40 μM butylated hydroxytoluene in methanol was added to stop
the reaction giving a ﬁnal (theoretical) protein concentration of
0.4 μg/mL. The mixture was dialysed against PBS (pH 7.4) at 4 °C using
a mini slide-a-lyser cassette (2 kDa cut-off; Thermo Scientiﬁc, Rockford,
IL, USA) for 2 h and then overnight in fresh, cold PBS. Following dialysis,
the sample was divided into aliquots and stored at−80 °C.
2.4. SDS-PAGE analysis of Pin1
Recombinant Pin1 protein (1 μg) and an equal volume of oxidised
recombinant Pin1 protein were mixed with 4× reducing sample buffer
(25% (w/v) glycerol, 2% (w/v) SDS, 62.5 mM Tris–HCl, pH 6.8, 32 mM
DTT and 0.005% (w/v) bromophenol blue) and PBS to a ﬁnal volume
Table 1
Patient demographics and protein levels.
Advanced AD pathologya Early AD pathologya Controlsa p-Valueb
Hippocampus
Age 79.1 (8.2); n = 9 81.9 (6.1); n = 10 79.6 (4.7); n = 5 ns
Gender; M/F 4/5 5/5 3/2 ns
Post-mortem delay (h) 4.6 (2.3) 4.4 (0.8) 4.5 (1.0) ns
oxPin1 (pg/μg total protein) 6103 (1719) 5810 (608) 5328 (850) ns
Pin1 (ng/μg total protein) 54.1 (9.6) 41.2 (6.8) 45.2 (7.3) p = 0.008
oxPin1:Pin1 ratio 0.113 (0.025) 0.143 (0.020) 0.118 (0.022) p = 0.018
Total protein (μg/mL) 13.6 (2.8) 13.4 (1.3) 14.9 (2.0) ns
Values are presented as mean (standard deviation) except where otherwise indicated; ns= non-signiﬁcant.
a Additional clinical information is provided in Supplementary Table S1. Advanced AD= Braak stage 5–6; early AD= Braak stage 3–4 and controls = Braak stage 0–2.
b p-Values obtained using ANOVA.
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of 16 μL. Samples were then heated to 95 °C for 5min, loaded on to SDS-
PAGE gels with 4% acrylamide stacking gel and 12% acrylamide running
gel, and electrophoresed at 200 V. Gels were stained with Coomassie
Brilliant Blue (R250, Serva) stain for 45min. The Precision Plus Protein™
Standard (All Blue) molecular weight marker (10–250 kDa; Biorad
Laboratories, Inc., California, USA) was used to approximate protein
size. Protein bandswere scanned using a BioRad Gel Doc 2000 apparatus
and density measurements were used to calculate oxPin1 concentration
in comparison to non-oxidised protein (Quantity One programme —
BioRad v.4.2.1).
2.5. Direct ELISA for carbonylated proteins
A direct ELISA for the measurement of carbonyl content in the pro-
tein samples with minor modiﬁcations from the original protocol [23]
was used to conﬁrm protein carbonylation as a measure of protein oxi-
dation. Protein samples derivatised with 2,4-dinitrophenyl hydrazine
(5 μM DNPH; 45 min) in 6 M GuHCl, pH 2.4 (1:3 ratio) were absorbed
onto an ELISA plate. The hydrazone adducts, 2,4-dinitrophenyl (DNP),
were detected using a biotinylated antibody directed against DNP
(Anti-Dinitrophenyl-KLH, Rabbit IgG Fraction, Biotin-XX Conjugate;
Molecular Probes®, Oregon, USA), followed by 20 min incubation with
100 μL of streptavidin-HRP complex (1:200 R&DDuoSet kit). The colour
reactionwas developedusing TMB substrate (30min at RT), stoppedwith
0.5MH2SO4 (50 μL) and read at 450 nm(Tecan Sunrise ELISAplate reader
andMagellan data analysis software). The extent of protein oxidationwas
assessed by comparisonwith an oxidised BSA standard. Oxidised BSA and
reduced BSA were prepared as previously described [15].
2.6. OxPin1 sandwich ELISA
OxPin1 levels in brain tissue were quantiﬁed using a novel home-
made sandwich ELISA with oxidised recombinant Pin1 as standard.
ELISA plates (F96 cert. MaxiSorp™ Immuno-plate: Nunc, Roskilde,
Denmark) were incubated overnight at 4 °C with polyclonal rabbit
anti-DNP (2 μg/mL in 1 M NaHCO3, pH 9.6; Life Technologies) and
washed (5× 300 μL, 0.05% Tween-20/phosphate buffered saline (PBST))
between all incubation steps. Plates were blocked with 0.1% BSA/PBS,
pH 7.4 (250 μL). Samples, standards (oxPin1, stock = 0.2 μg/μL) and
blank (PBS) were derivatised with 5 μM DNPH in 6 M GuHCl, pH 2.4
(1:3 ratio), vortexed, incubated for 45 min in the dark, and subsequently
diluted in sample diluent (1 mM EDTA, 0.5% Triton X-100 in PBS). The
highest standard (50 ng/mL) was serially diluted in sample diluent to
obtain a 6-point standard curve. Standards, blank (PBS) and tissue
samples (100 μL/well) were incubated for 2 h at room temperature
(RT)with agitation (650 rpm). An additionalwash step (1:1 ethanol:PBS)
was used to ensure the removal of unbound DNPH that could react with
the detection antibody. Detection antibody (250 ng/mL biotinylated
polyclonal goat anti-Pin1; R&D Pin1 DuoSet, #DYC2294) was applied
for 1 h followed by 20 min incubation with 100 μL of streptavidin-HRP
complex (1:200 R&D DuoSet kit). The colour reaction was developed
using TMB substrate (30 min at RT), stopped with 0.5 M H2SO4 (50 μL)
and read at 450 nm (Tecan Sunrise ELISA plate reader and Magellan
data analysis software).
2.7. Total Pin1 sandwich ELISA
Pin1 levels in brain tissue (diluted 1:25) were measured using a
commercially available ELISA kit (R&D DuoSet® IC for total Pin1;
Abingdon, UK) according to the manufacturer's instructions.
2.8. Statistical analysis
Between groups comparison was performed using Kruskal–Wallis
tests for non-Gaussian distributed data (oxPin1) and one-way analysis
of variance (ANOVA) or Student's t-test for Gaussian-distributed data.
Analysis of covariance (ANCOVA) was performed to control for covari-
ant inﬂuences such as age, gender and post-mortem delay.
3. Results
3.1. Conﬁrmation of Pin1 oxidation
Several oxidation conditions were tested and we found that oxida-
tion using 0.2 mM Fe(II)SO4, 10 mM H2O2 and 0.3 mM EDTA gave the
optimal results with respect to oxidation level versus protein degrada-
tion. Still, SDS-PAGE gel analysis (Fig. 1A) suggested that Pin1 was
partially degraded after oxidation. We noted a more slowly migrating
band for oxidised Pin1 than non-oxidised Pin1 (Fig. 1A) as has been
observed previously for other oxidised proteins [24–26] and we were
able to conﬁrm the band as Pin1 in western blot analyses using
both polyclonal and monoclonal anti-Pin1 antibodies (Fig. 1B). Using
band density measurements we calculated the concentration of
full-length oxidised Pin1 to be 0.2 μg/μL.We derivatised proteins (either
from recombinant source or from brain extracts) with DNPH and
immunoprecipitated these using anti-Pin1-coated protease G beads.
The derivatised proteins were detected with the anti-DNP antibody
and in this way we observed oxPin1 in the form of a detectable band
at the correct molecular weight expected for Pin1. However, the results
for the brain extract proteins gave inconsistent results when repeated
(data not shown). Oxidation of Pin1 was conﬁrmed using a direct
ELISA for detection of carbonyl side chains. Compared with untreated
Pin1, reduced BSA, and PBS treated with DNPH, high OD450 values in
the direct ELISA obtained for oxPin1 and oxidised BSA conﬁrmed their
oxidation status (Fig. 1C). Furthermore, the OD450 value for reduced
Pin1 did not differ signiﬁcantly from untreated Pin1 suggesting that
untreated Pin1 was not oxidised.
3.2. Validation of the sandwich ELISA for oxPin1
A typical standard curve for oxPin1 is shown in Fig. 2. Linearity was
observed up to 50 ng/mL. The lower limit of detection was 2.7 ng/mL.
Consistent with the results of direct ELISAs, PBS and non-oxidised
recombinant Pin1 (up to 50 ng/mL) treated in the derivatisation reac-
tion were detected at only very low levels (OD450 value consistently
less than 0.2; data not shown). Omission of capture antibody, detection
antibody or antigen gave absorbance values resembling the blank
conﬁrming the absence of cross-reaction of either capture or detection
antibodies with other proteins or each other. It also indicated that
neither the biotinylated Pin1 antibody nor brain tissue samples bind
non-speciﬁcally to the plate.
3.3. Levels of total protein, Pin1 and oxPin1 in brain extracts
Grouped patient demographics and protein levels are reported in
Table 1. Patients were divided into groups and analysed according to
Braak stage pathology as follows: Controls (Braak 0–2), early AD pathol-
ogy (Braak 3–4) and advanced AD pathology (Braak 5–6) [27]. Levels of
Pin1 and oxPin1 reported in the main text are reported per μg of total
protein. The clinical characteristics of individual patients are provided
in Supplementary Table S1.
Analysis of hippocampal tissue according to the degree of pathology
showed that Pin1 tended to be correlated with post-mortem delay in
controls (r = 0.872, p = 0.054) and was correlated with age in
advanced AD (r = 0.789, p = 0.012). No other correlations between
protein measurement and age, gender or post-mortem delay were
observed. When using ANCOVA to control for both age and post-
mortem delay, Pin1 levels, but not oxPin1 levels, were signiﬁcantly
higher in advanced AD pathology compared with both early pathology
(p b 0.01) and controls (p b 0.05; Fig. 3A and B). The oxPin1:Pin1 ratio
was signiﬁcantly higher in early pathology than controls (p b 0.05)
and advanced AD pathology (p = 0.01; Fig. 3C).
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4. Discussion
We designed a novel sandwich ELISA for the purpose of measuring
speciﬁcally oxidised proteins using measures of oxPin1 in biological
samples as an example. We demonstrate the successful application of
this novel sandwich ELISA to assess the levels of oxPin1 in human
hippocampal samples fromADpatients and healthy controls. In addition,
we show evidence of an increased ratio of oxPin1 to Pin1 in early AD
pathology which substantiates the need for further investigation of the
role of Pin1 and oxPin1 in the pathophysiology of AD. The design of
this ELISA has potential applications for the measurement of other
proteins that are speciﬁcally oxidised to produce carbonyl side chains
in AD and a wide range of neurodegenerative diseases that represent
potential biomarkers of disease.
In the current study, the ratio of oxPin1:Pin1 seemedmore informa-
tive than individual measurement of Pin1 or oxPin1 alone. When we
analysed the ratio of oxPin1:Pin1 in human hippocampal samples we
observed an increased ratio in the hippocampi of patients with early
AD pathology (Braak stage 3–4) compared with controls (Braak stage
0–2; p = 0.032). This is consistent with the notion that Pin1 is oxidised
in AD and that this occurs early in the disease process particularly since
wedid not observe an increase in the ratio of oxPin1:Pin1 in thepatients
with advanced AD pathology. This contradicts previous reports [7,12],
but we classiﬁed our samples according to Braak pathology to investi-
gate the relationship between levels of oxPin1 and the pathological
features of AD whereas the earlier studies used clinical diagnosis of
MCI and AD established by neurological and psychological assessment.
Thismay provide some explanation for differences between the studies.
We also noted that post-mortem delay tended to be correlated with
levels of Pin1 in the control samples. This could also potentially explain
differences between studies and should be further explored in future
studies.
Theﬁnding of increased oxPin1:Pin1 in the hippocampus of early AD
pathology is relevant in consideration of other research showing the in-
volvement of Pin1 in both the direct regulation of tau phosphorylation
and the indirect regulation via GSK3β and PP2A. Together, the observa-
tion that Pin1 is oxidised early in AD, and likely leads to its dysfunction,
helps to conﬁrm that oxidation of Pin1may lead to enhanced formation
of NFTs as it can no longer bind to and dephosphorylate the tau protein.
Interestingly, we observed an ~40% increase in Pin1 levels in the
hippocampus of patients with advanced AD pathology compared with
controls and an ~19% decrease in early stage AD pathology compared
with controls. The increase in Pin1 levels in the advanced pathology
samples was surprising as we expected from previous research that
Pin1 levels would be generally decreased in AD [12,28]. However, a
Fig. 1. Analysis of Pin1 oxidation. A) SDS-PAGE analysis (visualised with Coomassie Brilliant Blue staining) of Pin1 and oxidised Pin1. Recombinant Pin1 runs as a 17 kDa product
(lane 1) whereas oxPin1 has a slightly higher molecular weight (lane 2). B)Western blot analysis shows that Pin1 can be detected following oxidation. C) Direct ELISA for carbonyl
proteins. The high OD450 values obtained from the direct ELISA for carbonyl proteins shows oxidation of oxidised BSA (oxBSA) and oxidised Pin1 (oxPin1) whereas the very low signals
for reduced BSA (rBSA), non-oxidised Pin1 (Pin1) and the derivatised PBS blank (PBS (Blk)) show that these samples contain minimal carbonyl side chains. Bars show average OD values
from 4 experiments with error bars showing standard error of the mean. Ab: antibody.
Fig. 2. Standard line — oxPin1 sandwich ELISA. The graph shows average OD values for
each oxPin1 standard taken from 7 consecutive experiments. Bars show standard error
of the mean for each standard.
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more recent report using immunohistochemical methods showed
redistribution anddeposition of Pin1 into neuronal granules in the brains
of patients with advanced AD pathology compared with controls [29].
Rather than a reduction of Pin1, per se, in these tissues the immunohis-
tochemical investigations tended to suggest an abnormal accumulation
of Pin1 that might support our ﬁnding of increased Pin1 in advanced
AD pathology [29]. The correlation observed between severity of Pin1
granules and NFTs in patients with Braak stages 5–6 [29], although
weak, hints that levels of Pin1 may be associated with pathological
changes. Therefore, future studies could use a combination of ELISA
and immunohistochemical techniques to ﬁrmly establish associations
between oxPin1and Pin1 granules or NFTs.
In the current study, the use of a GuHCl protocol to extract proteins
from the brain tissue should have ensured the total extraction of Pin1
from all cell fractions including any that may have been accumulated
abnormally in granules but potentially could have affected Pin1 stabili-
ty. We do not believe that the latter was the case as repeated measures
of oxPin1 following freeze-thawing were consistent. In earlier experi-
ments, we also measured levels of oxPin1 in brain tissue extracted
using other extraction buffers, including RIPA carbonate, and AC/BT
(1.5 M aminocaproic acid, 75 mM Bis-Tris) buffers. However, levels of
oxPin1 in these samples were much lower than those measured in the
GuHCl extract and were often at, or below, the limit of detection.
We acknowledge that relatively small numbers of hippocampal
tissues limit our ability to generalise the ﬁndings to other AD patients.
In this study oxPin1 was only measured in brain tissue and showed
only moderate differences between the groups thus limiting its current
potential for use as a clinical biomarker. The main purpose of demon-
strating the use of our developed ELISA for the measurement of
oxPin1 in human hippocampal samples has been, however, adequately
achieved. The utility of the ELISA will need to be further examined in
studies including measures of Pin1 and oxPin1 not only in larger
numbers of patients but should also compare hippocampal levels with
levels in another brain area in which no, or only minimal, changes
might be expected (e.g. cerebellum).Wewere able to show that specif-
ically oxidised proteins can be measured in biological material. The de-
sign of our ELISA using an anti-DNP antibody to capture all carbonylated
proteins and speciﬁcally detect a target protein using a protein-speciﬁc
detection antibody enables its adaptation for measurement of other
potential disease-speciﬁc oxidised proteins such as alpha-synuclein in
Parkinson's disease [30–32], and glutamine synthetase in AD [7]. In ad-
dition, the use of antibodies to speciﬁc proteins reduces the likelihood of
measuring background interference from other carbonylatedmolecules
(e.g. nucleic acids and lipids), which can otherwise give interference [6].
Other adaptations using antibodies to measure alternative forms of
oxidative modiﬁcation (e.g. cysteine or methionine oxidation) might
be of high relevance for the measurement of some proteins. For
example, the oxidation of DJ-1 at its cysteine (Cys) residues has been
implicated in the pathogenesis of Parkinson's disease and might be of
interest for future studies. We have preliminary evidence that assays
adapted for the measurement of Cys-oxidised DJ-1 shows promise. For
this assaywe used puriﬁed recombinant Fab antibody fragments specif-
ically directed against Cys-oxidised DJ-1 as the capture antibody and a
biotinylated goat anti-human DJ-1 antibody for detection and could
use this assay to measure Cys-oxidised DJ-1 in brain tissue extracts
and some CSF samples but not in serum. However, these ELISAs will
require further optimisation to improve inter-assay reproducibility
and consistency in the background signal. The development of puriﬁed
antibodies directed against a speciﬁc form of oxidised protein would be
of beneﬁt in developing optimal ELISAs in future studies. Such studies
may reveal if protein oxidation is a global process in early stages of
neurodegenerative pathology.
5. Conclusions
We have developed a novel sandwich ELISA for themeasurement of
oxPin1 in human brain tissue and shown that the ratio of oxPin1:Pin1 is
increased in the hippocampus of early stage AD pathology compared
with both controls and advanced AD pathology. Further development
and modiﬁcation of the assay design will enable multi-functional use
for the quantiﬁcation of oxidised proteins in tissues and biological ﬂuids
thatmay be used in investigating the role of oxidised proteins in a range
of neurodegenerative diseases, particularly in which disease-speciﬁc
protein oxidation has been implicated.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2015.04.004.
Transparency documents
The Transparency documents associated with this article can be
found, in the online version.
Acknowledgements
This studywas supported by a grant from the Internationale Stichting
Alzheimer Onderzoek (ISAO, grant no. 08552) of The Netherlands.
Hippocampal material obtained from the Netherlands Brain Bank was
provided under Project number 707. We would like to thank Mareike
Müller for assistance with the preparation of hippocampal samples for
analysis, and Jorine Eeftens and Marie-Christine Bochem for technical
assistance.
References
[1] B.C. Dickinson, C.J. Chang, Chemistry and biology of reactive oxygen species in
signaling or stress responses, Nat. Chem. Biol. 7 (2011) 504–511.
[2] P.H. Axelsen, H. Komatsu, I.V.J. Murray, Oxidative stress and cell membranes in the
pathogenesis of Alzheimer's disease, Physiology 26 (2011) 54–69.
[3] K.J. Barnham, C.L. Masters, A.I. Bush, Neurodegenerative diseases and oxidative
stress, Nat Rev Drug Discov 3 (2004) 205–214.
Fig. 3.Protein levels in hippocampal tissue. Levels of Pin1per total protein (TP) (A) are increased in advancedADpathology (Braak stage5–6) comparedwith both controls (Braak stage0–2)
and early AD pathology (Braak stage 3–4) whereas levels of oxidised Pin1 (B) are not different between the groups. The ratio of oxPin1 to Pin1 (C) is increased in early AD pathology
compared with controls and advanced AD pathology. Signiﬁcance levels are those obtained from ANCOVA analysis: *p b 0.05 and **p b 0.01.
5M.K. Herbert et al. / BBA Clinical 4 (2015) 1–6
[4] G. Benzi, A. Moretti, Age- and peroxidative stress-related modiﬁcations of the
cerebral enzymatic activities linked to mitochondria and the glutathione system,
Free Radic. Biol. Med. 19 (1995) 77–101.
[5] B. Morgan, D. Ezeriņa, T.N.E. Amoako, J. Riemer, M. Seedorf, T.P. Dick, Multiple
glutathione disulﬁde removal pathways mediate cytosolic redox homeostasis, Nat.
Chem. Biol. 9 (2013) 119–125.
[6] A. Rogowska-Wrzesinska, K. Wojdyla, O. Nedić, C.P. Baron, H.R. Grifﬁths, Analysis of
protein carbonylation — pitfalls and promise in commonly used methods, Free
Radic. Res. 48 (2014) 1145–1162.
[7] D.A. Butterﬁeld, H.F. Poon, D. St. Clair, J.N. Keller, W.M. Pierce, J.B. Klein, W.R.
Markesbery, Redox proteomics identiﬁcation of oxidatively modiﬁed hippocampal
proteins in mild cognitive impairment: insights into the development of
Alzheimer's disease, Neurobiol. Dis. 22 (2006) 223–232.
[8] R. Sultana, M. Perluigi, S.F. Newman, W.M. Pierce, C. Cini, R. Coccia, D.A. Butterﬁeld,
Redox proteomic analysis of carbonylated brain proteins in mild cognitive
impairment and early Alzheimer's disease, Antioxid Redox Signal 12 (2010)
327–336.
[9] E. Cabiscol, J. Tamarit, J. Ros, Protein carbonylation: proteomics, speciﬁcity and
relevance to aging, Mass Spectrom. Rev. 33 (2014) 21–48.
[10] I. Dalle-Donne, R. Rossi, D. Giustarini, A. Milzani, R. Colombo, Protein carbonyl
groups as biomarkers of oxidative stress, Clin. Chim. Acta 329 (2003) 23–38.
[11] R.L. Levine, Carbonyl modiﬁed proteins in cellular regulation, aging, and disease,
Free Radic. Biol. Med. 32 (2002) 790–796.
[12] R. Sultana, D. Boyd-Kimball, H.F. Poon, J. Cai, W.M. Pierce, J.B. Klein, W.R.
Markesbery, X.Z. Zhou, K.P. Lu, D.A. Butterﬁeld, Oxidative modiﬁcation and
down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics
analysis, Neurobiol. Aging 27 (2006) 918–925.
[13] O.L. Lopez, J. J.W., T. D.S., J.T. Becker, A. Fitzpatrick, C. Dulberg, et al., Prevalence
and classiﬁcation of mild cognitive impairment in the cardiovascular health study
cognition study: part 1, Arch. Neurol. 60 (2003) 1385–1389.
[14] I. Landrieu, C. Smet-Nocca, L. Amniai, J.V. Louis, J.-M. Wieruszeski, J. Goris, V.
Janssens, G. Lippens, Molecular implication of PP2A and Pin1 in the Alzheimer's
disease speciﬁc hyperphosphorylation of Tau, PLoS One 6 (2011) e21521.
[15] S.M.K. Davies, A. Poljak, M.W. Duncan, G.A. Smythe, M.P. Murphy, Measurements
of protein carbonyls, ortho- and meta-tyrosine and oxidative phosphorylation
complex activity in mitochondria from young and old rats, Free Radic. Biol. Med.
31 (2001) 181–190.
[16] S.L. Ma, L. Pastorino, X.Z. Zhou, K.P. Lu, Prolyl isomerase Pin1 promotes amyloid
precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3β
(GSK3β) activity, J. Biol. Chem. 287 (2012) 6969–6973.
[17] S. Martić, S. Beheshti, H.-B. Kraatz, D.W. Litchﬁeld, Electrochemical investigations of
tau protein phosphorylations and interactions with Pin1, Chemistry & Biodiversity 9
(2012) 1693–1702.
[18] H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta
Neuropathol. 82 (1991) 239–259.
[19] H. Braak, E. Braak, Staging of Alzheimer's disease-related neuroﬁbrillary changes,
Neurobiol. Aging 16 (1995) 271–278.
[20] S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, L.M. Brownlee, F.S. Vogel, J.P.
Hughes, G.V. Belle, L. Berg, P.C. Neuropathologists, The Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD), Neurology 41 (1991) 479.
[21] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, Clinical
diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group*
under the auspices of Department of Health and Human Services Task Force on
Alzheimer’s Disease, Neurology 34 (1984) 939.
[22] G. Waldemar, B. Dubois, M. Emre, J. Georges, I.G. McKeith, M. Rossor, P. Scheltens, P.
Tariska, B. Winblad, Recommendations for the diagnosis and management of
Alzheimer's disease and other disorders associated with dementia: EFNS guideline,
Eur. J. Neurol. 14 (2007) e1–e26.
[23] M.A. Korolainen, T.A. Nyman, T. Aittokallio, T. Pirttilä, An update on clinical
proteomics in Alzheimer's research, J. Neurochem. 112 (2010) 1386–1414.
[24] E. Augustyniak, A. Adam, K. Wojdyla, A. Rogowska-Wrzesinska, R. Willetts, A.
Korkmaz, M. Atalay, D. Weber, T. Grune, C. Borsa, D. Gradinaru, R. Chand Bollineni,
M. Fedorova, H.R. Grifﬁths, Validation of protein carbonyl measurement: a
multi-centre study, Redox Biology 4 (2015) 149–157.
[25] N.B. Wehr, R.L. Levine, Wanted andwanting: antibody against methionine sulfoxide,
Free Radic. Biol. Med. 53 (2012) 1222–1225.
[26] X. Liang, A. Kaya, Y. Zhang, D. Le, D. Hua, V. Gladyshev, Characterization of
methionine oxidation and methionine sulfoxide reduction using methionine-rich
cysteine-free proteins, BMC Biochem. 13 (2012) 21.
[27] B.T. Hyman, J.Q. Trojanowski, Editorial on consensus recommendations for the
postmortem diagnosis of Alzheimer disease from the National Institute on
Aging and the Reagan Institute Working Group on Diagnostic Criteria for the
Neuropathological Assessment of Alzheimer Disease, J. Neuropathol. Exp.
Neurol. 56 (1997) 1095–1097.
[28] P.J. Lu, G. Wulf, X.Z. Zhou, P. Davies, K.P. Lu, The prolyl isomerase Pin1 restores the
function of Alzheimer-associated phosphorylated tau protein, Nature 399 (1999)
784–788.
[29] A. Dakson, O. Yokota, M. Esiri, E. Bigio, M. Horan, N. Pendleton, A. Richardson, D.
Neary, J. Snowden, A. Robinson, Y. Davidson, D.A. Mann, Granular expression of
prolyl-peptidyl isomerase PIN1 is a constant and speciﬁc feature of Alzheimer's
disease pathology and is independent of tau, Aβ and TDP-43 pathology, Acta
Neuropathol. 121 (2011) 635–649.
[30] J. Choi, M.C. Sullards, J.A. Olzmann, H.D. Rees, S.T. Weintraub, D.E. Bostwick, M.
Gearing, A.I. Levey, L.-S. Chin, L. Li, Oxidative damage of DJ-1 is linked to sporadic
Parkinson and Alzheimer diseases, J. Biol. Chem. 281 (2006) 10816–10824.
[31] J. Andersen, Oxidative stress in neurodegeneration: cause or consequence? Nat. Rev.
Neurosci. 5 (2004) S18–S25.
[32] C.B. Glaser, G. Yamin, V.N. Uversky, A.L. Fink, Methionine oxidation, α-synuclein
and Parkinson's disease, Biochimica et Biophysica Acta (BBA) — Proteins and
Proteomics 1703 (2005) 157–169.
6 M.K. Herbert et al. / BBA Clinical 4 (2015) 1–6
